The normal structure and function of CD44 and its role in neoplasia

R J S Sneath, D C Mangham

Abstract
CD44 is a transmembrane glycoprotein, the variant isoforms of which are coded for by alternative splicing, with the most prolific isoform being CD44 standard. CD44 is found in a wide variety of tissues including the central nervous system, lung, epidermis, liver, and pancreas, whereas variant isoforms of CD44 (CD44v) appear to have a much more restricted distribution. Variants of CD44 are expressed in tissues during development, including embryonic epithelia. Known functions of CD44 are cellular adhesion (aggregation and migration), hyaluronate degradation, lymphocyte activation, lymph node homing, myelopoiesis and lymphopoiesis, angiogenesis, and release of cytokines. The functions of CD44 are principally dependant on cellular adhesion in one setting or another. The role of CD44 in neoplasia is less well defined, although metastatic potential can be conferred on non-metastasising cell lines by transfection with a variant of CD44 and high levels of CD44 are associated with several types of malignant tumours. The physiological functions of CD44 indicate that the molecule could be involved in the metastatic spread of tumours. Many studies have investigated the pattern of CD44 distribution in tumours and some observations suggest that certain cells do not use CD44 in tumorigenesis or in the production of metastases. However, the data are extremely conflicting, and further studies are needed to establish the prognostic value of CD44 and its variant isoforms. The precise function of CD44 in the metastatic process and the degree of involvement in human malignancies has yet to be established fully.

Keywords: CD44; variant isoforms; cellular adhesion; tumorigenesis; metastasis

CD44 is a cell membrane molecule that was first identified on lymphocytes and was initially found to have cell adhesion and cell homing functions. Since its initial discovery, the antigen has been identified in most human tissues and has been found to have a multiplicity of functions.

In 1989, Stamenkovic and colleagues found that a variety of carcinoma cell lines and solid tumours expressed the CD44 gene. In 1991, Günther and colleagues discovered that an isoform of CD44 when inserted into the genetic sequence of a non-metastasising tumour gave it metastatic properties. These initial discoveries indicating that CD44 was involved in the metastatic process led to a large amount of research into the possible mechanisms and the degree of involvement of CD44.

Background
As with most clusters of differentiation antigens, several centres discovered the protein individually and each ascribed their own name to it. Previous names for CD44 include:
- Pgp-1 (Hughes and colleagues, Trowbridge and colleagues)
- ECMRIII (Carter and Wayner, Gallatin and colleagues)
- Hermes antigen (Jalkanen and colleagues)
- Ly-24, H-CAM and gp90Hermes (Haynes and colleagues)

Sequence studies and the use of monoclonal antibodies have revealed that all these molecules are identical. The International Workshop on Human Leukocyte Differentiation Antigens have ascribed the CD number 44 to the protein.

Structure and isoforms
CD44 is a glycoprotein encoded on the short arm of chromosome 11. The genetic sequence can code for a variety of different proteins by selecting certain exons within the sequence, that is, the gene contains constant and variable exons. Variation occurs at the transcription stage and the splicing together of variant exons to form mRNA is called alternative splicing.

The mechanism that controls alternative splicing is unknown, although there are reports of regulation of the CD44 promoter by the oncogene ras. Individual cells have the ability to change the pattern of their CD44 expression according to their needs.

The most prolific isoform of CD44 has been termed CD44 standard (CD44s) and is a protein of 37 kDa. The mRNA of this isoform contains no variant exons. There are a total of nine variant regions that can be coded for, v2–v10 (v1 was isolated in rats and is not present in human DNA). Variant CD44 (CD44v) can contain one or more variant regions, such as CD44v6 or CD44v3–v7. Many combinations of these variant exons are possible and individual cells can repeatedly change the splicing of CD44 pre-mRNA, giving the potential for great diversity. Using polymerase chain reaction (PCR) analysis, over 30 different splice products have been detected to date, and sequence diversity has been said to exceed that of any other known protein family created by alternative splicing.
The cytoplasmic domain interacts with the cytoskeleton of the cell. The degree of and nature of this interaction are, as yet, not fully understood. Neame and colleagues showed that the loss of the cytoplasmic tail did not alter many of the functions of CD44 and proposed a putative linker molecule interacting with the rest of the CD44 molecule. However, the cytoplasmic domain is required for distributing CD44 to specific areas of the cell and also increases the longevity of the molecule. The cytoplasmic tail also influences the binding of CD44 with hyaluronate, the molecule’s principal ligand.

CD44 is able to crosslink on the cell membrane, and the pattern of this crosslinking varies between CD44s and CD44v. Only CD44v can form oligomers, the molecules involved all being of the same isoform (homo-oligomerisation). Hyaluronan binding can be influenced by this crosslinking of CD44.

**Distribution of CD44 in normal tissues**

**ADULT TISSUES**

CD44s, as its name implies, was first isolated on haemopoietic cells. It has since been found on a wide range of tissues including the central nervous system, lung, epidermis, liver, and pancreas (table 1). CD44v appears to have a much more restricted distribution and is expressed on a variety of epithelial cells in a tissue specific pattern, suggesting that the process of alternative splicing is normally tightly regulated. This also suggests that these isoforms, with a specific exon sequence and restricted distribution, have different, additional functions to CD44s. Examples of cells expressing CD44v include keratinocytes, activated lymphocytes, macrophages, and some epithelial cells on the bladder, stomach, and uterine cervix.

As the table indicates, squamous epithelium has a high level of CD44s and CD44v expression. Keratinocytes express CD44s and at least five isoforms containing different numbers of variable exons including v2-v10, v3-v10, v4-v10, v6-v10, and v8-v10. In normal human keratinocytes, the main CD44 isoform, v3-v10, has both heparan sulphate and chondroitin sulphate side chains. Squamous epithelium has also been seen to express intron 9.

CD44 expression within an epithelial tissue can vary between layers and also between cells. Dall and colleagues reported that CD44v6 expression was limited to the stratum basale and the stratum spinosum of normal uterine cervical squamous epithelium. Korabiowska and colleagues reported that CD44 was not expressed in normal melanocytes and naevi, although the surrounding keratinocytes express CD44v3–10.

**Fetal tissues**

Numerous variants of CD44 have also been found to be expressed strongly on tissues during stages of development, including expression on embryonic epithelia. In the embryonic mouse, Yu and colleagues demonstrated variant expression in actively proliferating and...
invaginating epithelia at sites of epithelial–
mesenchymal interaction. The most prominent
of these variants were CD44v3–v10, CD44v4–
v10, and CD44v6–v10.

Physiological roles of CD44
The varied structure and distribution of CD44
suggests that the molecule has a variety of
functions. Known functions of CD44 are:
- cellular adhesion (aggregation and migra-
tion)
- hyaluronate degradation
- lymphocyte activation
- lymph node homing
- myelopoiesis and lymphopoiesis
- angiogenesis
- release of cytokines

CD44 functions are principally dependant
on cellular adhesion in one setting or another.
This adhesion can lead to interaction between
two different cells or between a cell and its
pericellular matrix.

CELL–MATRIX INTERACTIONS INVOLVING CD44
In view of the variety of isoforms and the wide-
spread tissue distribution of CD44, it is not
surprising that this molecule has more than one
ligand. These ligands include hyaluronate,
chondroitin, collagen, laminin, and
fibronectin. The main ligand for CD44
is hyaluronate. The amino-terminal (hyaluro-
nan binding) domain is a constant, highly
preserved feature of all CD44 isoforms. This
terminal domain is composed of two clusters of
positively charged amino acids, which bind
a six-sugar sequence of hyaluronate.

Hyaluronate is a very long, high molecular
weight polysaccharide molecule. It is distrib-
uted ubiquitously in the extracellular space of
higher animals. Hyaluronate has other recep-
tors such as the protein RHAMM (receptor for
hyaluronic acid mediated motility).

The cell’s ability to bind to hyaluronate via
CD44 is finely regulated. The clustering
effect of CD44 on the cell surface has been
shown to be necessary for the binding of
hyaluronate because it is a multivalent
interaction. An intact cytoplasmic domain is
also required for high affinity binding of
hyaluronate. This binding affinity increases
with molecular ionic strength because both
molecules are negatively charged and binding
is optimal at a neutral pH.

The ability of variant isoforms of CD44 to
bind hyaluronate is variable. It appears that,
although CD44v contains a hyaluronate bind-
ing domain, the molecule’s ability to bind
hyaluronate is reduced by the presence of its
variant exons. If part of the variant domain is
replaced by an alternative protein sequence the
molecule’s binding ability for hyaluronate
increases. This inhibitory effect of the variant
exons is additive, as a result of the degree of
their glycosylation. Binding studies show that
CD44v lacking O-linked glycosylation can
bind hyaluronate as efficiently as CD44s. N-
linked glycosylation has also been shown
to reduce the ability of CD44 to bind
hyaluronate. This regulatory glycosylation
can occur at the level of alternative splicing and
also at the level of expression of
glycosyltransferases.

The CD44 molecule is also involved in the
degradation of hyaluronate. The hyaluronate–
CD44 complex is internalised and then joined
to a lysosomal compartment, where acid
hydrolyses act upon it. This is an important
function of the CD44 molecule because build-
up of hyaluronate can have negative effects,
such as in the lung, where it could interfere
with gas exchange.

Proliferating cells express high amounts of
CD44. In these areas, hyaluronate concentra-
tions are low and it has been suggested that

---

**Table 1** Differential expression of CD44 variants in normal human tissue

<table>
<thead>
<tr>
<th>Tissue</th>
<th>CD44s</th>
<th>CD44v6</th>
<th>CD44v7</th>
<th>CD44v8</th>
<th>CD44v7 and v8</th>
<th>CD44v8 and v9</th>
<th>CD44v7, v8 and v9</th>
<th>Introns 9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>++</td>
</tr>
<tr>
<td>Gingiva</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Tongue</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Larynx</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td>Oesophagus</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td>Bronchus</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Lung</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td>Stomach</td>
<td>+++</td>
<td>+</td>
<td>+</td>
<td>+++</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Duodenum</td>
<td>+++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Jejunum</td>
<td>+++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Ileum</td>
<td>+++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Colon</td>
<td>+++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Rectum</td>
<td>+++</td>
<td>++++</td>
<td>++/+</td>
<td>++++</td>
<td>++/+</td>
<td>+++/+</td>
<td>++/+</td>
<td>+/+</td>
</tr>
<tr>
<td>Parotid gland</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Submandibular gland</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Thyroid gland</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Pancreas</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Adrenal gland</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Ovary</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Myometrium</td>
<td>+++</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Cervix</td>
<td>+++</td>
<td>++++</td>
<td>+++</td>
<td>++++</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Liver</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Bile duct</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Kidney, cortex</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Ureter</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Bladder</td>
<td>+++</td>
<td>++</td>
<td>++</td>
<td>++++</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Spleen</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>+++</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Expression: ++++, strong; ++, moderate; +, weak; −, negative.
localised degradation of hyaluronate leads to a morphological change in the tissue. Proliferating cells showing this expression include cells involved in the repair process, embryonic morphogenesis, organogenesis, and angiogenesis. In addition, it was discovered that semi-purified fragments of hyaluronidase degraded hyaluronate could stimulate the proliferation and migration of endothelial cells and accelerate angiogenesis in vivo. Interestingly, proliferating epithelial cells are typically rich in hyaluronate.

Smooth muscle cells involved in repair processes have been shown to upregulate both CD44 and the ligand, hyaluronate. Therefore, it has been suggested that smooth muscle cells establish an autocrine form of stimulation in the repair process.

Another CD44 ligand, chondroitin, is a polysaccharide and is closely related to hyaluronate. Chondroitin binds to the same region of the CD44 molecule as hyaluronate, the hyaluronan binding domain. Collagen, laminin, and fibronectin bind to CD44 by interaction with the chondroitin sulphate side chains that are linked to the core protein by glycosylation.

**CELL–CELL INTERACTIONS INVOLVING CD44**

CD44 is used by several cell types to mediate hyaluronate dependant adhesion. Aggregation of macrophages and lymphocytes is induced by exogenous hyaluronate. Cultured fibroblasts can aggregate spontaneously by using endogenous hyaluronate present on the cell.

Hyaluronate based adhesion is reduced in the presence of hyaluronidase, low levels of hyaluronate, high concentrations of chondroitin, or monoclonal antibodies to the hyaluronate receptor.

CD44 binding of hyaluronate is relatively weak in comparison to other cell adhesion mechanisms, such as those involving cadherins or integrins. This has been suggested to be an advantage where cells only need to be held close together for the exchange of chemical signals. This could account for its properties of activation and maturation of lymphocytes.

Exon v10 has a serine glycine motif that functions as a chondroitin sulphate attachment and is used in preference to the CD44 chondroitin/hyaluronate binding site. This moiety is recognised by other CD44 molecules and is bound. Exon v10 can promote homotypic and heterotypic cell–cell adhesion in vitro. Other exon specific attachments include exon v6, which has been shown to be a site of attachment in rats of the H blood group antigen. Glycosylation of exon v3 with heparan sulphate enables it to bind a subset of heparin binding growth factors, and cytokines including fibroblast growth factor b (bFGF) and heparin binding epidermal growth factor (HB-EGF). This binding can act as a reservoir for these substances.

More recent research has shown that another ligand for CD44, osteopontin (Eta-1; early T lymphocyte activation 1), is involved in CD44 dependent chemotaxis. Osteopontin has been shown to be involved in the regulation of inflammation, bone formation (osteogenesis), and angiogenesis, and this might depend on an interaction with CD44.

**LYMPH NODE HOMING AND LYMPHOCYTE ACTIVATION**

One of the main functions of CD44 is in lymph node homing and lymphocyte activation. Lymph node homing is achieved by a specific interaction between the middle domain of CD44s on lymphocytes and a protein, present on the high endothelial cells of Peyer’s patches and lymph nodes, called mucosal addressin.

The variant CD44v6 has been shown to have a crucial role in the movement and homing of antigen activated lymphocytes in lymph nodes. CD44v6 is also required for activation of B and T lymphocytes and maturation of stem cell progenitors. The precise mechanisms involved have yet to be elucidated, although it is thought that activation and interaction of lymphocytes require crosslinking of CD44, and additional cofactors and adhesion molecules. The costimulatory signal of CD44 is thought to depend upon signalling through CD2. The variants CD44v3 to CD44v6 have been shown to be expressed transiently as an early event on the blast cells of lymph nodes and the spleen after activation of lymphocytes.

**MYELOPOIESIS, LYMPHOPOIESIS, AND ANGIGENESIS**

CD44 is also involved in both myelopoiesis and lymphopoiesis. CD44v6 is required for maturation of the adherent stem cell population in what may involve v6 primarily transducing signals between stromal cells and stem cells, which initiate differentiation. Upon ligand and interaction, CD44s is thought to provide proliferation initiating signals for early progenitors of all three haematopoietic lineages.

Proliferation and migration, two features required in angiogenesis, are inhibited when a monoclonal antibody to CD44 is used on calf pulmonary arterial endothelial cells.

**Role of CD44 in neoplasia**

Tremendous interest in CD44 was generated when Günthert and colleagues conferred metastatic potential on a non-metastasising cell line by transfecting a variant of CD44. The initial work was to identify the membrane proteins on a metastasising rat pancreatic adenocarcinoma by the use of monoclonal antibodies. These antibodies were screened on a bacterial cDNA expression library and one of the cDNA clones was found to encode a variant isofrom of CD44. This cDNA was transfected into a non-metastasising, rat pancreatic adenocarcinoma, which although expressing CD44s, did not express this particular variant. The new cell line was found to have gained metastatic properties when injected into rats (syngeneic animals). This phenomenon was also demonstrated in mammary carcinoma cell lines. Guo and colleagues showed that monoclonal antibody specific for CD44s can...
completely inhibit the binding of cells of a human melanoma cell line (SMMU2) to hyaluronate in vitro and also inhibit the metastatic capability of the tumour cells in vivo. In addition, if the monoclonal antibody to CD44 was given seven days after tumour inoculation, the primary tumour continued to grow, although the tumour’s metastatic capability was completely inhibited.

Hofmann and colleagues\(^{26}\) noted that the expression of CD44v6 by CREF (cloned rat embryonic fibroblasts) cells correlated with metastatic behaviour. In immunocompromised animals, the expression of low amounts of CD44v6 was sufficient to confer metastatic ability. CD44v6 expression by these cells could be increased by transfecting the activated oncogene ras. It has been reported that further mutations are needed to account for the amount of overexpression by highly metastatic cell lines.\(^{26}\)

In support of this initial experimental evidence implicating the involvement of CD44 in neoplasia, it has been seen that high amounts of CD44 are associated with several types of malignant tumours. These include carcinomas, high grade gliomas, and a number of non-Hodgkin’s lymphomas.\(^{17}\) High concentrations of hyaluronate have also been found in many tumours.\(^{37}\) The invasiveness of certain tumours has also been correlated with CD44 and hyaluronate concentrations.\(^{77-79}\)

**ROLE OF CD44 IN TUMORIGENESIS**

There are many potential theories about the possible mechanisms involved with respect to the role of CD44 in tumorigenesis.

CD44 expression is associated with a high rate of cell division. The proliferation status of tumour cells increases when cultured on anti-v6 antibody coated plates. CD44v6 on the cell surface is thought to crosslink with other CD44v6 molecules, initiating signals of growth promoting activity.\(^{41}\) Interactions between CD44 and its ligands might induce the tumour cells to produce autocrine growth factors. These factors might be critical for tumour growth. The functions of CD44 beyond cellular adhesion require the transmission of intracellular signals. Some of these signals are thought to occur via the cytoskeleton and might enable CD44 to signal to both the locomotory\(^{42}\) and mitogenic machinery of the cell.\(^{42}\)

Tumour cells expressing CD44 can adhere to the extracellular matrix through its ligands, including hyaluronan, chondroitin sulphate, fibronectin, laminin, collagen, and matrigel. This might allow tumour cells to colonise these environments more efficiently. The functions of uptake and degradation of hyaluronate by CD44 could enable tumour cells to invade hyaluronate rich tissues. In a panel of breast cancer cell lines, hyaluronate degradation mediated by CD44 correlated better than CD44 expression itself with invasiveness.\(^{38}\)

Cytoplasmic staining of CD44 might be indicative of hyaluronate uptake and was found to be prevalent in a comprehensive panel of tumours.\(^{24}\) This cytoplasmic staining was also accentuated at the infiltrating tumour margin, which would be consistent with the proposed role of CD44 in tumour invasion.\(^{37}\) Tissue specific infiltration might require CD44v6 expression. This appears to be the case in infiltration of the skin, where CD44v10 is expressed by the infiltrating tumour.\(^ {31}\)

**ROLE OF CD44 IN METASTASIS FORMATION**

Metastatic spread requires a series of interactions between the tumour cells and the surrounding extracellular matrix and non-tumour cells. These interactions will depend on cell surface determinants such as extracellular receptors for matrix and basal lamina, surface bound proteolytic enzymes, cell adhesion molecules, growth factors, and growth factor receptors.\(^{7}\) The metastasising tumour cell copies the same mechanisms of normal cellular migration. From the review of the physiological functions of CD44 it can be seen that CD44 can function as a cell surface determinant for several of the roles required for metastatic spread to occur.

The function of CD44v in the metastatic process can be blocked by a monoclonal antibody to CD44v. However, this observation does not reveal which step or steps CD44 is involved in, although the monoclonal antibody has to be given early on to block the metastatic process.\(^ {82,83}\)

The theoretical steps of the metastatic process are known as the metastatic cascade\(^ {84,85}\) and they consist of: (1) loss of contact with the surrounding tumour cells or neighbouring cells; (2) breakthrough of the basement membrane and penetration of vessel walls; (3) survival of shearing forces in the bloodstream/lymph stream; (4) adhesion and penetration through the vessel walls; (5) expansion into foreign tissue; (6) induction of vascularisation of tumour.

For a tumour cell to lose contact with neighbouring tumour cells, its adhesive properties must change. Changing the cell’s CD44 profile could certainly achieve this. Increased expression of CD44 can enhance binding to hyaluronate and a pericellular matrix of hyaluronate might decrease the affinity of a cell for surrounding hyaluronate deficient cells by interfering with adhesion processes, thus leading to detachment. This increased mobility is thought to be initiated by CD44 because it is linked to the cell’s cytoskeleton.\(^ {42,80}\) A CD44–ligand complex could mediate the mechanical force and transmit intracellular locomotory signals via the cytoskeleton. This response could lead to the cells enhanced movement along hyaluronate rich surfaces.\(^ {24}\) As previously discussed, CD44 has the ability to take up and degrade hyaluronate,\(^ {16}\) and this property could allow tumour cells to escape entrapment within hyaluronate rich environments.

Migration of any cell to the vascular or lymphatic system requires both cell adhesion molecules and cell surface enzymes. The ability of CD44 to degrade hyaluronate could also be used by the tumour cell to assist in its path through the basement membrane and vessel wall. Tumour cells that metastasise by way of the lymphatic system are thought to imitate...
lymphocytes, entering peripheral lymphatics and travelling to the draining lymph nodes. Variants of CD44 are involved in the activation of lymphocytes and the release of cytokines. CD44s is required for lymphocyte homing within the lymphatics to the high endothelial venules within lymph nodes. In a lymphoma animal model, CD44 monoclonal antibodies did not inhibit spleen metastases developing, whereas they did affect the incidence of metastases to the lymph nodes. These observations imply that special variant isoforms of CD44 may be involved in the specific homing of tumour cells.

CD44 might also assist in distant metastatic adherence within the vascular system, with the adhesion molecule attaching to a known, or as yet unknown ligand. Tumours that produce a high concentration of hyaluronate might initiate aggregation through CD44s. This aggregate could become trapped in the capillary system as an embolus and invade through the vessel wall. CD44 also has a potential role in the next step of the metastatic cascade, which has been mentioned earlier in the role of CD44 in tumorigenesis. This is the potential of CD44 to assist in the penetration through vessel walls and expansion into foreign tissue. Vascularisation of the newly embedded tumour may well involve CD44, which has been shown to be important in angiogenesis.

**CD44 in specific tumour types**

Since the initial research showing the potentially crucial role of CD44 in tumorigenesis and the metastatic cascade, there have been many studies investigating the pattern of CD44 distribution in tumours.

Because CD44 is expressed in a wide variety of tissues, many studies have compared CD44 expression by particular tumours and their normal tissue counterpart. Tumours originating from epithelia that normally carry variants of CD44 on their surface remain positive for CD44v and often produce higher concentrations of CD44 transcripts. However, this finding is not uniform. Hudson and colleagues found that squamous cell carcinomas arising from stratified squamous epithelium had a reduced expression of one or more of the variant exons that are expressed normally. This reduced expression of CD44 variants was greatest in the least differentiated regions and in distant metastases. Squamous cell carcinomas also showed changes in expression of other adhesion molecules, such as integrins.

Certain observations suggest that some cells do not use CD44 in tumorigenesis or in the production of metastases. In neuroblastoma, Burkitt’s lymphoma, and melanoma CD44 variants are often absent. In one study, absence of CD44s correlated with poor survival in patients with neuroblastoma. In another study, transfection of CD44s into a highly metastatic rat prostate carcinoma cell line showed that this molecule acted as a metastasis suppressor gene, although the in vivo growth rate and tumorigenicity of the cell line were not suppressed.

**CD44 EXPRESSION IN LUNG CARCINOMA**

Givechian and colleagues discovered that squamous cell carcinomas arising from the lung retain the CD44 expression profile of the normal respiratory epithelium, whereas all other types of lung cancer showed a significantly reduced, or absent, expression of either standard or variant CD44. These experiments did not provide any evidence for the presence of tumour or metastasis associated CD44 transcripts with an altered exon composition compared with CD44 transcripts expressed in the normal respiratory epithelium. The findings in the non-squamous cell carcinomas also suggested that downregulation of CD44s and CD44v might contribute to metastatic spread, rather than enhanced expression of specific variant CD44 isoforms.

**CD44 EXPRESSION IN GASTROINTESTINAL CARCINOMAS**

An interesting finding by Higashikawa and colleagues was the expression of a CD44 intron by colorectal tumours. In non-malignant tissues, the intron 9 sequence is found in squamous epithelia and to a lesser degree, transitional and respiratory epithelia. Overexpression of variants containing intron 9 was also found in intestinal metaplasia. The authors suggested that intron expression might be a tumour specific abnormality, except possibly in squamous epithelia. If tumour progression follows physiological genetic programmes, the possibility that colorectal tumours are using a variant of CD44 that serves a physiological function in squamous epithelium must be considered.

Higashikawa and colleagues also found that all the colorectal adenocarcinomas they examined overexpressed high molecular weight CD44 transcripts including the v6 exon. The CD44v6 variant was not found to correlate with tumour stage or metastatic status and was suggested to be a common phenotype of colorectal cancer. However, some studies have found the CD44v9 variant to be an independent prognostic indicator for gastrointestinal tumours. Mayer and colleagues found that CD44v9 expression in primary gastric cancers had a statistical correlation with tumour recurrence and mortality. Yamaguchi and colleagues found that the rate of CD44v8–v10 expression was significantly higher in tumours from patients with liver metastases than those without, but the authors could find no correlation between CD44v8–v10 expression and prognosis. However, in a later paper, Yamaguchi and colleagues found CD44v8–v10 expression to be an independent prognostic indicator for colorectal carcinoma. Takanashi and colleagues have found that expression of CD44s by colon carcinoma cells enhances their hyaluronate binding, and this enhancement appears to reduce both in vitro and in vivo growth of the carcinoma cells. The authors also report that the hyaluronate binding activity of CD44 was less pronounced in highly metastatic cell lines compared with poorly metastatic cells lines. The differences in hyaluronate binding ability were suggested to
be caused by post-translational modifications. These observations led to the conclusion that the functional consequences of the association of decreased CD44s expression with colonic mucosa transformation might just be as important as increased expression of high molecular weight variants of CD44 by tumours.

Different types of gastric cancer have different patterns of CD44 expression. The intestinal type of gastric cancer has a predominant expression of CD44v6, whereas the diffuse type is mostly CD44v6 negative. It is interesting that the CD44v6 positive intestinal type appeared to have a more infiltrative type of growth compared with the CD44v6 negative diffuse type. Müller and colleagues found no correlation between C44v6 expression in gastric carcinoma and prognosis. CD44v5 expression correlated with significantly shorter overall survival times, although this significance was lost with the use of multivariate analysis.

CD44 EXPRESSION IN BREAST CARCINOMA
Research with melanoma cell lines has revealed that transfection of a CD44 negative melanoma cell line with cDNA for the CD44s molecule promotes tumorigenicity. Further work showed that growth and metastasis of melanoma cells can be inhibited by monoclonal antibodies to CD44, and that the degree of CD44 expression correlates with the size of the pulmonary metastases produced. In addition, lymph node metastases had a significantly higher expression of CD44 antigen when compared with the primary tumour. It is interesting that melanocytes and naevi do not express CD44 within an epithelium which does express the molecule, and that melanomas appear to require CD44 for tumorigenicity. Also epithelia are, obviously, matrix free. Dansin and colleagues reported that uveal melanomas that arise from retinal epithelium appear to express a different CD44 pattern when compared with cutaneous melanomas. CD44v6 tends to be expressed by in situ uveal melanomas and not cutaneous melanomas and vice versa for CD44v5. The authors suggest that the microenvironment of the melanoma cells influences expression of this variant.

CD44 EXPRESSION IN BREAST CARCINOMA
Studies looking into CD44 expression in breast carcinomas have indicated that expression could be regulated by hormones. Increases in the expression of oestrogen and progesterone receptors showed a positive correlation with CD44v6. Several studies have evaluated CD44 expression in breast carcinomas with conflicting results. Sinn and colleagues found a correlation between expression of CD44v3/v4 and CD44v6 and increased tumour grade, whereas Friedrichs and colleagues found a correlation between expression of CD44s and CD44v9 and tumour grade. Neither study found CD44 or any of its variants to be independent prognostic indicators, as was the case in a similar study by Kaufmann et al. Differences between studies might result from varying techniques of recognition. Using immunohistochemistry, Sinn and colleagues showed a higher expression of CD44 at the tumour–stroma interface and that all regional lymph node metastases were homogeneously positive for variants of CD44. A more recent study, using immunohistochemistry on 218 primary breast carcinomas, found that CD44s and CD44v6 did not correlate with known predictors of poor prognosis.

CD44 EXPRESSION IN PROSTATE CARCINOMA
Preliminary studies on carcinoma of the prostate indicate altered expression of CD44 in these tumours.

CD44 EXPRESSION IN LEUKAEMIA
Rossi and colleagues found that CD44s was overexpressed in approximately half their cases of B cell chronic lymphocytic leukaemia, although CD44v5 and CD44v6 expression was usually found to be normal. Raised serum CD44s concentrations were associated with a number of unfavourable prognostic factors and the authors proposed that the molecule might be a reliable tumour marker.

CD44 EXPRESSION IN OVARIAN CARCINOMA
Ermak and colleagues showed that papillary cancers of the thyroid also appear to follow certain restricted patterns of CD44 variant expression. Several CD44 isoforms are not detectable in normal thyroid tissue and CD44v6 and CD44v7 are coexpressed in a tightly coupled manner in these thyroid cancers.

CD44 EXPRESSION IN OVARIAN CARCINOMA
Sluijs and colleagues showed that ovarian tumour samples exhibit a more complex pattern of CD44 expression than normal ovarian tissue, and proposed that this expression is reflected in its serum concentration. However, the variants of CD44 detected in the serum did not correlate with any clinical parameter, and it was suggested that the dominant serum CD44 variants were produced by natural sources masking the pathological output.
CD44 EXPRESSION IN SARCOMAS

There has been comparatively little research done on the expression of CD44 by sarcomas. Wang and colleagues discovered that most sarcomas express CD44s. Certain sarcomas appeared to have a higher incidence of CD44s expression (epithelioid sarcoma and angiosarcoma) compared with others (clear cell sarcoma and liposarcoma). Immunohistochemical staining of the cytoplasm was also reported, which might represent hyaluronic uptake.24 No correlations between CD44s positivity and clinical outcome could be made because of the relatively small numbers. Our own research114 has shown that there is no correlation between CD44s or variant isoform expression and clinical outcome in synovial sarcomas.

In summary, the above studies have produced wildly conflicting data. Most papers suggest that this results from a lack of consistency in experimental method. Some studies rely on PCR analysis whereas others generate data from immunohistochemical analysis. Different monoclonal antibodies have been used to detect the presence of the same isoform, some antibodies being more sensitive than others.

Conclusion

CD44 is a ubiquitous transmembrane cell surface molecule. Its principal physiological functions are in the aggregation, migration, and activation of cells, and these occur through the adhesive qualities of the molecule. CD44 is overexpressed by many tumours, and the pattern of expression often differs from that of the tissue of origin. This feature might be useful in screening these tumours using PCR analysis. CD44 is able to endow certain non-metastatic cell lines with metastatic properties and this effect can be blocked by monoclonal antibodies to CD44. CD44 possesses a number of properties that are required by a metastasising cell. Expression of CD44 and variants of CD44 have been correlated with clinical outcome in several human malignancies, although these findings are not consistent between various published studies. Further studies are required with standardisation of methodologies, larger study samples, and longer clinical follow up periods to establish the prognostic significance of CD44 and its variant isoforms.

The precise function of CD44 in the metastatic process and the degree of involvement in human malignancies has yet to be established fully.
Structure and function of CD44 and its role in neoplasia

37 Cooper D, Doughtery G. Tometastasizeornot? Selectionof
36 Underhill C, Green S, Comoglio P,
35 Underhill C, Toole B. Receptorsforhyaluronateonthesur-
34 Jalkanen S, Jalkanen M, Bargatze R,
33 Lees V, Fan T, West D. Angiogenesis in a delayed
32 Lesley J, Hyman R. CD44canbeactivatedtofunctionasan
31 Bennett K, Modrell B, Greenfield B,
30 Kincade P. Molecularinteractionsbetweenstromalcellsand
29 Miyake K, Medina K, Hayashi S,
28 Jalkanen S, Bargatze R, DeLosToyes J,
27 Peach R, Hollenbaugh D, Stamenkovic I,
26 Wayer E, Carter W. Identification ofmultiplecelladhesion
25 Webb D Shimizu Y, Seventer van G,
24 Aru
23 Wager V, Amiot M, Amiot M,
22 Bennett K, Jackson D, Simon J,
21 Salmi M, Grön-Virta K, Sointu P,
20 Namec R, Toole B, Knudson T. Thecellsurfacehyaluronate
19 Hofmann M, Rudy W, Günthert U,
18 Aruffo A, Amiot M, Amiot M,
16 Reinholt F, Hultenby K, Oldberg A,
15 Müller W, Schneiders A, Heider K-H,
14 Mayer B, Jauch K, Günthert U,
13 Gao A, Lou W, Dong J-T,
12 Gao A, Lou W, Dong J-T,
11 Gao A, Lou W, Dong J-T,
10 Labarriere N, Jain J, Otry C,
9 Bennett K, Jackson D, Simon J, et al. CD44 isoforms
8 Bennett K, Jackson D, Simon J, et al. CD44 isoforms
7 Bennett K, Jackson D, Simon J, et al. CD44 isoforms
6 Bennett K, Jackson D, Simon J, et al. CD44 isoforms
5 Bennett K, Jackson D, Simon J, et al. CD44 isoforms
4 Bennett K, Jackson D, Simon J, et al. CD44 isoforms
3 Bennett K, Jackson D, Simon J, et al. CD44 isoforms
2 Bennett K, Jackson D, Simon J, et al. CD44 isoforms
1 Bennett K, Jackson D, Simon J, et al. CD44 isoforms


The normal structure and function of CD44 and its role in neoplasia.

R J Sneath and D C Mangham

Mol Path 1998 51: 191-200
doi: 10.1136/mp.51.4.191

Updated information and services can be found at:
http://mp.bmj.com/content/51/4/191

These include:

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/